InventisBio is a dynamic and fast-growing global biotech company with multiple therapeutic agents at clinical stage. InventisBio focuses on discovery and development of novel therapeutics in the areas of oncology and metabolic diseases to address unmet medical needs. The company was founded by a group of scientists with extensive R&D and management experience in global pharmaceutical companies. InventisBio's headquarter and R&D center are located in Pharma Valley of Shanghai Zhangjiang Hi-Tech Park, with an office in New Jersey, US for clinical operation as well. Currently, Inventisbio has three drug candidates in clinical development in both China and US targeting non-small cell lung cancer (NSCLC), breast cancer, and gout. The company’s philosophy is to exert the spirit of artisans in the discovery, development and delivery of high-quality and innovative therapies that benefit patients.
Dr. Lu is a well-known lung cancer expert, specializing in the diagnosis and treatment of various common lung diseases and the treatment of difficult and critically ill lung diseases. He has a high attainment for the early diagnosis of lung cancer, targeted therapy for lung cancer and comprehensive treatment.
Drug review expert of the State Food and Drug Administration
Director of Oncology Department of Thoracic Hospital, Shanghai Jiaotong University
Executive Director/Deputy Secretary of the Chinese Society of Clinical Oncology (CSCO), Member of the Department of International Affairs of the American Society of Clinical Oncology (ASCO)
Chairman of the China Anti-Cancer Society Lung Cancer Patient Committee and member of the Chinese Medical Association Oncology Branch
Dr. O'Shaughnessy is a renowned breast and blood disease expert. Her main research focus is the prevention and treatment of breast cancer.
Co-Chair of Breast Cancer Research of American Cancer Society
Member of the United States Oncology Research (USOR) Scientific Advisory Board
Baylor Sammons Cancer Center, Dallas, USA
Copyright @2019 InventisBio (Shanghai) co., LTD31011502002476 Shanghai ICP